This narrative review looked at how to manage oral potentially malignant disorders and oral squamous cell carcinoma. The authors noted that standard histopathological grading often lacks reliability. They also pointed out the inherent biological heterogeneity of these lesions makes simple grading difficult. Because of these issues, the review highlights a need for molecularly informed risk assessment in modern healthcare settings. No specific medications or interventions were tested in this review, so no safety data or side effects were reported. The study did not report a specific sample size or follow-up period. Readers should understand that this is a narrative review rather than a clinical trial with new data. The main takeaway is that current grading methods have limits. Doctors might consider molecular tools to help evaluate risk more accurately. This approach could help catch dangerous changes earlier or avoid unnecessary surgery. However, this review does not prove that molecular tests work better. More research is needed to confirm these ideas in real patients.
Molecular markers may improve risk assessment in oral potentially malignant disordersMolecular tools may improve risk assessment for oral lesions
AI-generated summary of the cited source, checked by automated accuracy review. How we work
This narrative review addresses the clinical challenge of risk stratification for oral potentially malignant disorders (OPMDs), which have an inherent risk of progressing to oral squamous cell carcinoma. The authors critique the limited reliability of conventional histopathological grading, noting that it fails to capture the biological heterogeneity of these lesions. They argue that molecular markers could offer a more precise, individualized risk assessment, aligning with the shift toward molecularly informed medicine. The review does not present pooled data or specific molecular targets but synthesizes conceptual arguments for integrating genomic, proteomic, or epigenetic biomarkers into clinical workflows. Limitations acknowledged include the lack of standardized molecular panels and the need for validation in prospective cohorts. The authors stop short of recommending specific markers, emphasizing that the field is still evolving. For clinicians, the takeaway is that histopathology alone may be insufficient, and future risk assessment will likely incorporate molecular profiling, though routine use is not yet supported by robust evidence.